The Menarini Group
http://www.menarini.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From The Menarini Group
With Hopeful Interim Data, Ultragenyx Bets On GeneTx, Angelman Syndrome Candidate
Ultragenyx is buying its Angelman syndrome partner GeneTx for $75m on the heels of an interim Phase I/II readout that shows signs of clinical activity and appears to resolve earlier safety worries.
Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand
The Roivant-owned company's Vtama topical cream was approved by the US FDA with a broad label permitting use for mild, moderate or severe psoriasis.
Minute Insight: Guardant Launches Shield Test To Detect Colorectal Cancer In Average-Risk Adults
The Shield lab-developed test was validated in a 309-patient study, demonstrating 91% sensitivity for colorectal cancer. The company is sponsoring the ECLIPSE study to support a PMA for the test.
The Quality Lowdown: Rewarding Your Best Quality Critics
Lupin hires former nemesis at FDA, how Baker exposed Hisun’s ‘full investigation,’ Cetylite’s many methods for overcoming OOS results, old school inspection-driven recalls at Vitae Enim Vitae Scientific and a critique of Catalent filling line’s non-deliberate response to the pandemic.
Company Information
- Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Hematology, Coagulation
- Urine-based Testing
- Other Names / Subsidiaries
-
- A. Menarini Diagnostics S.r.l.
- Berlin Chemie AG
- Invida Group Private Limited
- Lusofarmaco
- Menarini Asia-Pacific Holdings (Menarini AP)
- VaxYnethic